Milestone Pharmaceuticals Inc. Segments Disclosure
20. Segment Reporting
The Company manages its operations as a operating segment for the purpose of assessing performance and making operating decisions while focusing on the development and commercialization of innovative cardiovascular medicines. These operations are focused on a single product, which are reported on a consolidated basis. The accounting policies of the single operating segment are the same as those described in the summary of significant accounting policies. The chief operating decision maker, or “CODM,” assesses performance of the Company’s single operating segment based on consolidated net loss. Net loss is used by the CODM to evaluate budget to actual analytics, which are used to monitor the single segment spend and confirm the Company is meeting established budgetary goals. The CODM is the principal officer group, which includes the Company’s chief executive officer and chief financial officer.
The following table presents information about the Company’s significant expenses, as provided to the Company’s CODM, and includes a reconciliation to consolidated net loss:
Year ended December 31, | ||||||||
(in thousands) | | 2025 | | 2024 | ||||
Revenue | $ | 1,546 | $ | — | ||||
Less: | ||||||||
Research and development, net of tax credits, excluding share-based compensation | 15,744 | 12,483 | ||||||
General and administrative, excluding share-based compensation |
| 13,441 |
| 13,571 | ||||
Commercial, excluding share-based compensation |
| 27,040 |
| 10,272 | ||||
Share-based compensation expense | 7,461 | 5,776 | ||||||
Interest income |
| (2,920) | (4,164) | |||||
Interest expense | 3,838 | 3,581 | ||||||
Net loss | $ | (63,058) | $ | (41,519) | ||||
The measure of segment assets is reported on the balance sheet as total consolidated assets.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 20, 2026 | Showing above |
| 2024 | Mar 13, 2025 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.